{"id":68216,"date":"2026-06-15T21:40:37","date_gmt":"2026-06-15T13:40:37","guid":{"rendered":"https:\/\/flcube.com\/?p=68216"},"modified":"2026-06-15T21:40:38","modified_gmt":"2026-06-15T13:40:38","slug":"novo-nordisk-to-fully-launch-sogroya-in-china-this-summer-for-pediatric-growth-hormone-deficiency","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68216","title":{"rendered":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novo Nordisk (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>)<\/strong> announced that its <strong>long-acting growth hormone injection Sogroya (somapacitan)<\/strong> will be <strong>fully launched in China this summer<\/strong>, offering a <strong>once-weekly treatment option<\/strong> for <strong>Chinese pediatric patients aged 2.5 years and older<\/strong> with <strong>growth retardation due to insufficient endogenous growth hormone secretion<\/strong>. This marks a significant expansion of Novo Nordisk&#8217;s endocrinology portfolio in the world&#8217;s second-largest pharmaceutical market.<\/p>\n\n\n\n<h2 id=\"h-product-launch-details\" class=\"wp-block-heading\">Product Launch Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Sogroya (somapacitan)<\/td><\/tr><tr><td><strong>Launch Timeline<\/strong><\/td><td>Summer 2026<\/td><\/tr><tr><td><strong>Market<\/strong><\/td><td>China (full commercial launch)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pediatric growth hormone deficiency (GHD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Children aged 2.5 years and older with growth retardation<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Once-weekly subcutaneous injection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-advantages\" class=\"wp-block-heading\">Product Profile &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Long-acting growth hormone analog (somapacitan)<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Once-weekly dosing vs. daily injections required by conventional growth hormone therapies<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Recombinant human growth hormone with albumin-binding technology for extended half-life<\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Improved treatment adherence and quality of life through reduced injection frequency<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Simple once-weekly subcutaneous injection<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-amp-commercial-history\" class=\"wp-block-heading\">Regulatory &amp; Commercial History<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. FDA Approval<\/strong><\/td><td>August 2020<\/td><td>Adult growth hormone deficiency (AGHD)<\/td><\/tr><tr><td><strong>Global Launch<\/strong><\/td><td>2020-2026<\/td><td>Launched in 12 countries worldwide<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>Current<\/td><td>63% market share in launched markets<\/td><\/tr><tr><td><strong>China Introduction<\/strong><\/td><td>Early 2025<\/td><td>Clinically urgent imported drug at Boao Future Hospital<\/td><\/tr><tr><td><strong>China Full Launch<\/strong><\/td><td>Summer 2026<\/td><td>Comprehensive commercial availability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-china-market-opportunity-analysis\" class=\"wp-block-heading\">China Market Opportunity Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric GHD Prevalence:<\/strong> Estimated 30,000-50,000 diagnosed pediatric GHD patients in China<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong> Dominated by daily growth hormone injections with adherence challenges<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Significant demand for convenient, long-acting alternatives<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Once-weekly convenience supports premium pricing strategy<\/li>\n\n\n\n<li><strong>Healthcare Access:<\/strong> Growing insurance coverage for endocrine disorders in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-competitive-positioning\" class=\"wp-block-heading\">Strategic Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Among the first long-acting growth hormone therapies available in China<\/li>\n\n\n\n<li><strong>Novo Nordisk Brand Strength:<\/strong> Leverages company&#8217;s established reputation in diabetes and endocrinology<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> 63% global market share demonstrates strong physician and patient preference<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes against daily recombinant human growth hormone products from domestic and international manufacturers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-strategy-amp-implementation\" class=\"wp-block-heading\">Commercial Strategy &amp; Implementation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Physician Education:<\/strong> Comprehensive training programs for endocrinologists and pediatric specialists<\/li>\n\n\n\n<li><strong>Patient Support Programs:<\/strong> Injection training, adherence support, and financial assistance initiatives<\/li>\n\n\n\n<li><strong>Hospital Partnerships:<\/strong> Collaboration with major pediatric hospitals and endocrinology centers<\/li>\n\n\n\n<li><strong>Distribution Network:<\/strong> Leveraging Novo Nordisk&#8217;s established China commercial infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-broader-portfolio-integration\" class=\"wp-block-heading\">Broader Portfolio Integration<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This launch complements Novo Nordisk&#8217;s expanding presence in China beyond its core diabetes franchise, establishing the company as a comprehensive endocrinology solutions provider. The success of Sogroya globally (63% market share) provides strong validation for its clinical and commercial potential in the Chinese market.<\/p>\n\n\n\n<h2 id=\"h-future-development-opportunities\" class=\"wp-block-heading\">Future Development Opportunities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Additional Indications:<\/strong> Potential expansion to other growth-related disorders<\/li>\n\n\n\n<li><strong>Combination Therapies:<\/strong> Exploration with other endocrine treatments<\/li>\n\n\n\n<li><strong>Digital Health Integration:<\/strong> Connected injection devices and patient monitoring platforms<\/li>\n\n\n\n<li><strong>Regional Expansion:<\/strong> Further penetration across tier 2 and tier 3 cities in China<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding product launches, market opportunities, and commercial expectations. Actual results may differ due to risks including regulatory changes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68217,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[40,148,860],"class_list":["post-68216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-launch","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk&#039;s endocrinology portfolio in the world&#039;s second-largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk&#039;s endocrinology portfolio in the world&#039;s second-largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:40:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:40:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency\",\"datePublished\":\"2026-06-15T13:40:37+00:00\",\"dateModified\":\"2026-06-15T13:40:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1509.webp\",\"keywords\":[\"Market launch\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68216#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68216\",\"name\":\"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1509.webp\",\"datePublished\":\"2026-06-15T13:40:37+00:00\",\"dateModified\":\"2026-06-15T13:40:38+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk's endocrinology portfolio in the world's second-largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68216\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk's endocrinology portfolio in the world's second-largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68216","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency","og_description":"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk's endocrinology portfolio in the world's second-largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=68216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:40:37+00:00","article_modified_time":"2026-06-15T13:40:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency","datePublished":"2026-06-15T13:40:37+00:00","dateModified":"2026-06-15T13:40:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68216"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","keywords":["Market launch","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68216#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68216","url":"https:\/\/flcube.com\/?p=68216","name":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68216#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","datePublished":"2026-06-15T13:40:37+00:00","dateModified":"2026-06-15T13:40:38+00:00","description":"Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be fully launched in China this summer, offering a once-weekly treatment option for Chinese pediatric patients aged 2.5 years and older with growth retardation due to insufficient endogenous growth hormone secretion. This marks a significant expansion of Novo Nordisk's endocrinology portfolio in the world's second-largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68216"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68216#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","width":1080,"height":608,"caption":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68216\/revisions"}],"predecessor-version":[{"id":68218,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68216\/revisions\/68218"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68217"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}